Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Executive Summary
Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.
You may also be interested in...
Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus
Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.
Roche Not Ruling Out Creative Deals For ‘Tail End’ Brands
A better value proposition and more in-tune marketing ideas would drive a more creative risk-sharing or asset swap-like arrangement for the oncology specialist’s more mature brands, says Roche CEO Severin Schwan.
Biopharma Dealmaking Quarterly Statistics, Q1 2014
Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.